Ceftriaxone is NOT a first-line agent for uncomplicated brucellosis but serves as a reasonable option for complicated brucellosis (particularly neurobrucellosis) when combined with doxycycline and rifampicin.
First-Line Treatment Recommendations
The optimal treatment for uncomplicated brucellosis should be doxycycline 100 mg twice daily for 6 weeks combined with either streptomycin 15 mg/kg daily IM for 2-3 weeks (AI recommendation) or rifampicin 600-900 mg daily for 6 weeks (AI recommendation) 1. Gentamicin 5 mg/kg daily parenterally for 7 days represents an acceptable alternative to streptomycin (BI recommendation) 1.
Role of Ceftriaxone in Brucellosis
When to Consider Ceftriaxone
Ceftriaxone should be reserved for:
- Neurobrucellosis (most important indication)
- Complicated brucellosis with organ involvement (e.g., epididymo-orchitis, endocarditis)
- Pregnant women who cannot receive tetracyclines
- Patients intolerant to first-line agents
Evidence Base and Limitations
The evidence for ceftriaxone in brucellosis is mixed and concerning:
Monotherapy fails: An Israeli multicenter trial showed that 6 of 8 patients (75%) treated with ceftriaxone ≤2g daily IM failed initial therapy, requiring switch to doxycycline-streptomycin 2. This definitively establishes that ceftriaxone monotherapy should never be used.
Success in complicated cases: A case series of 6 patients receiving ceftriaxone 2g IV every 12 hours (notably higher dosing than the failed monotherapy studies) showed clinical cure in all cases—4 with neurobrucellosis, 1 with epididymo-orchitis, and 1 uncomplicated case 3.
Neurobrucellosis data: Multiple studies support ceftriaxone as part of combination therapy for neurobrucellosis, with treatment durations of at least 6 weeks to 6 months 4, 5, 6.
Recommended Dosing When Used
For complicated brucellosis (especially neurobrucellosis): Ceftriaxone 2g IV every 12 hours (total 4g daily) in combination with doxycycline 100 mg twice daily and rifampicin 600-900 mg daily 3, 4, 5.
Duration: Minimum 6 weeks for neurobrucellosis, with some experts recommending up to 6 months depending on clinical response and CSF normalization 4, 5.
Critical Pitfalls to Avoid
Never use ceftriaxone as monotherapy: The 75% failure rate in the Israeli trial is unacceptable 2. Even the earlier study showing 69% response rate with 2g twice daily noted this was inferior to standard therapy 7.
Inadequate dosing: The failed studies used ≤2g daily total. When ceftriaxone is indicated, use 2g IV every 12 hours (4g total daily) 3.
Wrong clinical scenario: Ceftriaxone is not indicated for uncomplicated brucellosis when standard regimens can be used. The Ioannina guidelines do not include ceftriaxone in their treatment table for uncomplicated disease 1.
Insufficient treatment duration: For neurobrucellosis, treating for less than 6 weeks increases relapse risk. One study emphasized minimum 6-month therapy for optimal outcomes 4.
Practical Algorithm
For uncomplicated brucellosis:
- Use doxycycline + streptomycin OR doxycycline + rifampicin
- Do NOT use ceftriaxone
For neurobrucellosis or severe complications:
- Start triple therapy: Ceftriaxone 2g IV q12h + doxycycline 100mg PO q12h + rifampicin 600-900mg daily
- Continue for minimum 6 weeks, extending to 6 months based on CSF normalization and clinical response
- Monitor CSF parameters regularly
For pregnant women:
- Consider ceftriaxone + rifampicin (avoid doxycycline)
- Alternative: trimethoprim-sulfamethoxazole + rifampicin 8
Microbiological Considerations
Recent susceptibility data from Turkey showed 100% susceptibility of Brucella species to ceftriaxone, along with gentamicin, rifampicin, tetracycline, trimethoprim-sulfamethoxazole, and streptomycin 9. This confirms ceftriaxone maintains in vitro activity, but the clinical failure data emphasizes that in vitro susceptibility does not guarantee clinical efficacy in monotherapy due to Brucella's intracellular location.